A ROADMAP FOR COOPERATION WITH PHARMAGIGANT NOVO NORDISK WILL BE DEVELOPED

On January 25, at the site of the Single Distributor SK-Pharmacy, a meeting was held with representatives of Novo Nordisk, namely with the new head of the company, Rana Asfar Zafar. The event was also attended by Timur Biabulin, head of the department for work with state and public structures, Anara Mekebayeva, head of cooperation with European countries, Guldaria Manakpayeva, executive director of the PharmMedindustry of Kazakhstan Association, and representatives of SK-Pharmacy.

The parties discussed ongoing joint work, as well as further detailed plans within the framework of the Memorandum concluded between the pharmaceutical giant Novo Nordisk and the Ministry of Health of the Republic of Kazakhstan.

The agreement involves active cooperation in supporting and developing the domestic production of medicines, providing quality medical care through the implementation of projects for continuing medical education in the field of diabetes and obesity, building up scientific and research potentials, and ensuring earlier access to innovative therapies for patients with diabetes mellitus and obesity.

Within the framework of cooperation, Novo Nordisk cooperates with the Ministry of Health of Kazakhstan in the field of clinical trials for the treatment of diabetes mellitus, the provision of continuing education for healthcare professionals "Global Obesity clinics program" and programs to train Kazakhstani endocrinologists in modern methods of treatment.

At the moment, in pursuance of the Memorandum, work is underway to develop and approve the Roadmap with the participation of the Association "PharmMedindustria of Kazakhstan" and "Kazakh Invest", where all specific activities will be prescribed.

In addition, special attention is paid to the support and development of domestic production of medicines. At the moment, potential local sites are being identified for the supply to the market of an active pharmaceutical ingredient for the production of human insulins under the brand of Kazakhstani pharmaceutical enterprises.

During the meeting, the Chairman of the Board of SK-Pharmacy, Erkhat Iskaliyev, noted that an important aspect in the framework of cooperation are projects in the field of conducting clinical trials throughout Kazakhstan. In the future, it is planned to organize a study of a drug for the treatment of diabetes mellitus in real clinical practice, in accordance with international requirements for this type of research and in accordance with the legislation of the country.

Representatives of Novo Nordisk, in turn, noted their interest in assessing the opportunities of the Kazakhstani market and exploring potential partnerships in the field of supporting local manufacturers, as well as their readiness to implement joint projects to develop the country's pharmaceutical sector and increase access to the services of specialized specialists.

It is worth noting that since 2010 SK-Pharmacy has been purchasing 17 types of drugs from Novo Nordisk, of which 9 are through a direct contract with the manufacturer's factory.

To date, pharmaceutical giants are involved in a variety of healthcare-related projects in the Republic of Kazakhstan, from vaccine development to clinical trials. Thus, joint work within the framework of the Memorandum concluded with Novo Nordisk contributes to the development of the healthcare sector, the expansion of the country's pharmaceutical market and the formation of Kazakhstan's human resources potential.

Reference:

Novo Nordisk, Novo Nordisk is a Danish pharmaceutical company. The headquarters is in Bagsvær, a suburb of Copenhagen. In the 2021 Forbes Global 2000 list of the largest public companies in the world, Novo Nordisk was ranked 260th (505th in terms of turnover, 81st in net income, 1274th in assets and 66th in market capitalization).

Novo Nordisk is a manufacturer of pharmaceutical products, in particular in the field of diabetes treatment (80% of sales). In addition, the company is engaged in the treatment of obesity (6% of sales), biopharmaceuticals, growth hormone treatment, and hormone replacement therapy.

Since 1991, the company has been increasing the availability of the most advanced drugs, as well as conducting large-scale clinical trials, developing and implementing new effective strategies for disease prevention and promotion of a healthy lifestyle. The company has been represented in the Republic of Kazakhstan since 1993.